With a wealth of experience in the customized antibody development field, Creative Biolabs now offers high-quality in vitro diagnostic (IVD) antibody development services to our global clients. Especially, we target one of the potential biomarkers of bladder cancer, the semenogelin-2 marker, to help our global clients with the development of novel diagnostic assays.
Introduction of the Semenogelin-2 Marker
Semenogelins, seminal plasma motility inhibitors predominantly secreted by the seminal vesicle, are the main structural components of human semen coagulum. As a member of semenogelins, semenogelin-2 is a protein that encoded by the human SEMG2 gene. It is associated with the formation of a gel matrix that encases ejaculated spermatozoa. Proteolysis by the prostate-specific antigen (PSA) breaks down the gel matrix and allows the spermatozoa to move more freely. Furthermore, studies have shown that semenogelin-2 is also expressed in tissues unrelated to fertility, such as breast, salivary glands, trachea, kidney and intestine, and in lung cancer cell lines, which indicates that this protein may be involved in functions beyond reproduction.
Semenogelin-2 Marker of Bladder Cancer
As a major coagulating protein in human semen, semenogelin-2 is usually expressed restricted to males. In addition, it has been reported that semenogelin-2 can also be detected in two small cell lung carcinoma cell lines from female patients. Even though the role of semenogelins in human malignancy is still poorly understood, various studies have suggested that semenogelins have a correlation with numerous cancers, including lung carcinomas, melanoma, and leukemias. Most importantly, the expression level of semenogelin-2 is much higher in the bladder cancer patient's urine sample when compared with normal people. In addition, studies have shown that semenogelin-2 have prognostic significance in the prediction of cancer progression after radical prostatectomy. In this case, semenogelin-2 has been served as the great biomarker and the potential therapeutic target for bladder cancer.
Fig.1 Western blot analysis of urine samples from healthy subjects and bladder carcinoma (BCa) patients.1
IVD Antibody Development Services Targeting Semenogelin-2 Marker
Proteomic biomarkers have become popular during the past decade. Blood, urine, prostatic fluids, and prostatic tissue have been evaluated as biomarker source. Numerous candidate biomarkers found in those studies were introduced as biomarkers for discrimination of indolent and advanced disease. As a pioneer company in IVD market, Creative Biolabs has provided a full range of IVD antibody development services for our global customers. With our versatile IVD platform, Creative Biolabs is proud to develop novel semenogelin-2-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates). We are happy to design and perform unique protocols to provide the most high-quality and cost-effective services to promote our client's programs development.
If you are interested in the services we provide, don't hesitate to contact us or send us an inquiry.
Reference
For Research Use Only.
